NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 121 filers reported holding NURIX THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $80 | -19.2% | 10,131 | +2.0% | 0.00% | – |
| Q2 2023 | $99 | -44.1% | 9,931 | -50.2% | 0.00% | – |
| Q1 2023 | $177 | -48.1% | 19,937 | -35.8% | 0.00% | – |
| Q4 2022 | $341 | -99.9% | 31,037 | +0.0% | 0.00% | -100.0% |
| Q3 2022 | $404,000 | +3.3% | 31,025 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $391,000 | +23.3% | 30,876 | +36.5% | 0.00% | – |
| Q1 2022 | $317,000 | -51.5% | 22,621 | +0.1% | 0.00% | -100.0% |
| Q4 2021 | $654,000 | -3.7% | 22,588 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $679,000 | -5.3% | 22,674 | -16.1% | 0.00% | 0.0% |
| Q2 2021 | $717,000 | +26.5% | 27,034 | +48.2% | 0.00% | 0.0% |
| Q1 2021 | $567,000 | +65.3% | 18,240 | +74.7% | 0.00% | – |
| Q4 2020 | $343,000 | +55.2% | 10,440 | +64.7% | 0.00% | – |
| Q3 2020 | $221,000 | – | 6,340 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |